MK-0557
- Generic Name
- MK-0557
- Drug Type
- Small Molecule
- Chemical Formula
- C22H19FN4O3
- CAS Number
- 328232-95-7
- Unique Ingredient Identifier
- HVE36P8422
- Background
MK0557 has been investigated for the treatment of Schizophrenia and Paranoid Schizophrenia.
Efficacy of MK0557 in Combination With Sibutramine or Orlistat (0557-015)(COMPLETED)
Phase 2
Completed
- Conditions
- Obesity
- First Posted Date
- 2007-09-21
- Last Posted Date
- 2016-09-16
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 497
- Registration Number
- NCT00533481
A Study to Determine the Effects of MK0557 in Obese Subjects (0557-006)(COMPLETED)
Phase 2
Completed
- Conditions
- Obesity
- First Posted Date
- 2007-09-21
- Last Posted Date
- 2016-09-07
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Registration Number
- NCT00533598
MK0557 for the Treatment of Cognitive Impairment in Patients With Schizophrenia (0557-027)
- First Posted Date
- 2007-06-05
- Last Posted Date
- 2015-08-21
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 50
- Registration Number
- NCT00482430
A 2-Year Study of an Investigational Drug in Obese Patients (0557-011)
Phase 3
Completed
- Conditions
- Obesity
- First Posted Date
- 2004-09-28
- Last Posted Date
- 2017-01-02
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 1500
- Registration Number
- NCT00092859
A 1-Year Study of an Investigational Drug in Obese Patients (0557-012)(COMPLETED)
Phase 3
Completed
- Conditions
- Obesity
- First Posted Date
- 2004-09-28
- Last Posted Date
- 2015-01-30
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 359
- Registration Number
- NCT00092872
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath